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Summary. Megakaryocytes were analyzed for their ability to
endocytose factor V to define the cellular mechanisms
regulating this process. In contrast to fibrinogen, factor V
was endocytosed by megakaryocytes derived from CD34+
cells or megakaryocyte-like cell lines, but not by platelets.
CD41+ ex vivo-derived megakaryocytes endocytosed factor
V, as did subpopulations of the megakaryocyte-like cells
MEG-01, and CMK. Similar observations were made for
fibrinogen. Phorbol diester-induced megakaryocytic differen-
tiation of the cell lines resulted in a substantial increase in
endocytosis of both proteins as compared to untreated cells
that did not merely reflect their disparate plasma concentra-
tions. Factor IX, which does not associate with platelets or
megakaryocytes, was not endocytosed by any of the cells
examined. Endocytosis of factor V by megakaryocytes
proceeds through a specific and independent mechanism as
CHRF-288 cells endocytosed fibrinogen but not factor V,
and the presence of other plasma proteins had no effect on
the endocytosis of factor V by MEG-01 cells. Furthermore,
as the endocytosis of factor V was also demonstrated to
occur through a clathrin-dependent mechanism, these com-
bined data demonstrate that endocytosis of factor V by
megakaryocytes occurs via a specific, independent, and most
probably receptor-mediated, event.
Keywords: clathrin, endocytosis, factor V, megakaryocyte,
platelet, receptor.
Introduction
Platelets contain numerous proteins involved in hemostasis
within their a-granules including von Willebrand factor
(VWF), plasminogen activator inhibitor-1 (PAI-1), thrombo-
spondin, fibrinogen, vitronectin and factor V, which are
released upon platelet activation at sites of vascular injury.
As platelets possess little, if any, biosynthetic capability, these
proteins are either synthesized by platelet precursors, mega-
karyocytes, or endocytosed from the plasma. VWF, thrombo-
spondin and PAI-1 are known to be synthesized by
megakaryocytes [1–3] and not endocytosed from the plasma
[4,5]. Plasma-derived fibrinogen, in contrast, is endocytosed by
bothmegakaryocytes and platelets [6,7], most likely through an
integrin-dependent mechanism [7]. No fibrinogen biosynthesis
has been detected in megakaryocytes [8] despite the presence of
its mRNA in these cells [9]. Vitronectin is also endocytosed by
megakaryocytes [4], and possibly platelets as its receptor, avb3,
is found in platelet a-granules [10].
The origin of platelet-derived factor V appears unique in that
it appears tobederived fromonlymegakaryocyte endocytosisof
the plasma-derived cofactor. This notion is supported by
analyses of platelet-derived factor V from individuals hetero-
zygous [11,12] orhomozygous [13] for factorVLeiden following
transplant of livers from wild-type factor V donors. In these
studies, the phenotype of the platelet-derived factor V pool
mimicked that of the plasmamolecule, and was independent of
the megakaryocyte factor V gene. As blood-borne platelets
cannot bind [14] or endocytose factor V [11], these combined
data support the hypothesis that the origin of platelet-derived
factor V is via endocytosis of the plasma molecule by megak-
aryocytes. Thus, both plasma- and platelet-derived factor V are
synthesized by the liver [15]. Subsequent to its endocytosis,
factor V is cleaved proteolytically to the active cofactor, and
rendered resistant to phosphorylation catalyzed by a platelet-
associated kinase [16]. These data are consistent with several
observations suggesting that platelet-derived factor V is func-
tionally and physically distinct from its plasma counterpart
[17–22]. In addition, several clinical observations suggest that
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once it is converted to factorVa, the essential protein cofactor in
thrombin production [23], it may play a more pre-eminent role
inmaintaining normal hemostasis [23,24]. Taken together these
observations represent a new paradigm whereby an essential
coagulant protein is endocytosed from plasma and modified
intracellularly to yield a functionally distinct molecule.
In contrast to observations in the human system, the murine
plasma- and platelet-derived factor V pools appear to be
biosynthetically distinct [25,26], an observation that is consis-
tent with earlier studies demonstrating factor V synthesis by
guinea pig megakaryocytes [27]. However, it should be noted
that fundamentally important cross-species differences have
been demonstrated inmammalian coagulation systems [28–31],
suggesting that some animal studies may not model the human
system appropriately.
The purpose of this study was to demonstrate directly that
human megakaryocytes endocytose factor V from plasma and
to begin to define the cellular processes regulating the endocytic
process. Our observations strongly support the concept that
megakaryocytes endocytose factor V by a specific, clathrin-
dependent and, most probably, receptor-mediated mechanism.
Materials and methods
Proteins
Thrombopoietin (TPO), human transferrin and human factor
VIII were generous gifts of Drs Dan Eaton (Genentech, San
Francisco, CA, USA), Anne Mason (University of Vermont),
and Kenneth Mann (University of Vermont), respectively.
Stem cell factor was from R & D Systems (Minneapolis, MN,
USA) and human factor IX was from Haematologic
Technologies, Inc. (Essex Junction, VT, USA) Human factor
V [32] and fibrinogen [33] were purified from fresh-frozen
plasma and characterized as described. Factor V was iodinated
with 125I and characterized as described previously [18]. Factor
V and transferrin were fluorescently labeled with AlexaFluor
dyes using commercially available kits (Molecular Probes, Inc.,
Eugene, OR, USA) at fluorescence to protein (F : P) ratios of
1.5–11.7 mol fluorophore per mol protein. AlexaFluor488-
labeled fibrinogen was also fromMolecular Probes, Inc. (F : P
ratio ¼ 8.1–15). Endocytosis was not affected by protein
modification as different preparations of modified proteins
yielded similar, if not identical, results, and the data obtained
mirrored those using unlabeled proteins followed by detection
with fluorescently labeled monoclonal antibodies (mAbs).
Purified mouse mAbs against human factor V, fibrinogen
and factor IX were obtained from the Core Antibody Facility,
at the University of Vermont, and labeled with AlexaFluor488
at F : P ratios ranging from 4 to 6. All other antibodies were
obtained commercially.
Megkaryocyte production ex vivo
Bone marrow cells were obtained from vertebral bodies
acquired from the National Disease Resource Interchange,
Philadelphia, PA. CD34+ hematopoietic progenitor cells were
isolated and subjected to ex vivo expansion and differentiation
into megakaryocytes as described [34].
Megakaryocyte-like cell lines
MEG-01 cells were from the American Type Culture Collec-
tion (Manassas, VA, USA) and were cultured following the
supplier’s directions. CMK [35] and CHRF-288 [36] cells,
generous gifts of DrHava Avraham (HarvardMedical School)
and Dr Michael Lieberman (University of Cincinnati College
of Medicine), respectively, were cultured as described. Quies-
cent cells were used for all experiments.
Where indicated, MEG-01 and CMK cells were stimulated
with phorbol myristate acetate PMA [1 · 10)8 mol L)1 in
dimethyl sulfoxide at 2 · 105 cells mL)1] for 3 days in media
containing 10% fetal bovine serum [37]. Following removal of
nonadherent MEG-01 cells, the adherent cells were removed
with phosphate-buffered saline containing 0.53 mM EDTA
(10 min, 37 C), and used in subsequent assays. CHRF-288
cells were stimulated with PMA (1 · 10)8 mol L)1 at 2 · 105
cells mL)1) for 2–5 days in media containing 20% horse
serum.
Analyses of factor V endocytosed by ex vivo-derived
megakaryocytes
CD34+ bone marrow cells were subjected to ex vivo
expansion and differentiation into megakaryocytes for 7 or
10 days. On days 4 or 7, factors V (30 nmol L)1) or IX
(90 nmol L)1) were added for 72 h. For immunocytochem-
ical localization of endocytosed protein, cells were adhered
to slides, air-dried, then fixed and permeabilized with
methanol. Cells, adhered to slides, were incubated with
1% horse serum and anti-factor V (66.7 nmol L)1) or anti-
CD41 (66.7 nmol L)1, Dako Corporation, Carpinteria, CA,
USA) mAbs (45 min). Unless otherwise indicated all
incubations were performed at ambient temperature. Anti-
factor V or anti-CD41 immunostaining was detected using
Immunopure ABC-Horseradish Peroxidase or -Phosphatase
staining kits (Pierce, Rockford, IL, USA), respectively.
Double antibody staining reactions were performed by
sequential immunostaining for factor V and then CD41.
Non-specific binding interactions were identified using
isotyped-matched, non-immune antibody or secondary anti-
body alone. The cell nuclei were counterstained using Evans
Blue.
For flow cytometric analyses of endocytosed protein, the
cells were labeled with anti CD41-phycoerythrin (PE) (45 min),
then washed, fixed, permeabilized and counterstained with
AlexaFluor488-labeled anti-factor V (66.7 nmol L)1) or anti-
factor IX (66.7 nmol L)1) mAbs (45 min). Fluorescence from
10 000 cells was analyzed on a FACscan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Two-color
analyses were accompanied by single-antibody staining to
allow adequate compensation of each fluorescence detector.
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The positive gate was set such that ‡97% of the cells
stained with isotyped-matched, non-immune antibodies were
negative. Megakaryocyte ploidy analyses were performed as
described [34].
Analyses of factor V endocytosed by megakaryocyte-like
cells
Untreated or PMA-treated cells (1 · 106 mL)1) were cultured
in serum-free media, containing 0.1% endotoxin-free bovine
serum albumin, in the presence or absence of plasma concen-
trations of unlabeled or AlexaFluor-labeled factor V
(30 nmol L)1), fibrinogen (10 lmol L)1), factor IX (90
nmol L)1), or transferrin (0.3 lmol L)1) for 1, 4, or 16 h
(37 C). Where necessary, washed cells were fixed with 2%
paraformaldehyde (30 min), followed by permeabilization with
0.15% Triton X-100 (15 min). Endocytosed protein was
detected by incubation (30 min) with immunostaining reaction
mixtures containing human immunoglobulin G (IgG) Fc
fragment (66.7 nmol L)1, Calbiochem, La Jolla, CA, USA)
and 0.1 lmol L)1 of the appropriate AlexaFluor488-labeled
mAb. Fluorescence from 10 000 cells was analyzed on a
Coulter EPICS Elite Flow Cytometer.
Following incubation with AlexaFluor-labeled proteins,
10 000 washed and fixed cells were adhered to poly L-lysine
(2 mg mL)1) coated slides, and visualized using an Olympus
BX50 Upright Fluorescence Microscope. The AlexaFluor488
and AlexaFluor568 fluorophores were excited at 488 and
568 nm, respectively, with a krypton/argon laser. The individ-
ual fluorescent images were merged using Bio-Rad LASER PIX
image analysis software. Colocalization was quantified using
the MetaMorph Imaging System (Universal Imaging Cor-
poration, Dauningtown, PA, USA).
Immunostaining for clathrin and a-adaptin
PMA-treated CMK cells were cultured with AlexaFluor488-
labeled factorV (30 nMOLL)1) or transferrin (0.3 lmol L)1) for
4 h (37 C). The cells were fixed and permeabilized as described
above and incubated (30 min) with humanFc (66.7 nmol L)1),
and mouse anti-clathrin or mouse anti-a-adaptin mAbs
(66.7 nmol L)1, BD Biosciences, San Jose, CA, USA). Reac-
tivity with the mAbs was detected with goat anti-mouse
IgG-AlexaFluor568 (66.7 nmol L)1, Molecular Probes)
(30 min). The cells were analyzed by confocal microscopy as
described above.
Disruption of clathrin-dependent, receptor-mediated
endocytosis by cell culture in hypertonic tissue culture media
PMA-stimulated CMK cells were washed twice with serum-
free medium, cultured in normal tissue culture medium or
tissue culture medium made hypertonic by the addition of
0.45 mol L)1 sucrose (30 min), and incubated with Alexa-
Fluor488-labeled factor V (30 nmol L)1), fibrinogen
(0.83 lmol L)1), or transferrin (0.3 lmol L)1) for 60 min.
The cells were analyzed by confocal microscopy or flow
cytometry as described above. The viability of the cells was
unaffected by their culture in hypertonic tissue culture media.
Quantification of MEG-01 or CMK cell binding and/or
endocytosis of 125I-labeled-factor V
MEG-01 or CMK cells (± PMA stimulation) were cultured in
serum-free media containing 30 nmol L)1 factor V plus trace
125I-labeled factor V (1 · 107 c.p.m. mL)1). Aliquots of the cell
suspension were removed at timed intervals (0–21 h), layered
over anApiezonA oil : n-butylpthalate mixture (1 : 9, v/v) in a
microcentrifuge tube, and centrifuged (12 000 · g, 30 s). The
radioactivity associated with the cell pellets, which represented
both cell-bound and internalized 125I-labeled factor V, was
determined using a c-counter.
The specificity of the binding interaction regulating factor V
endocytosis was determined using CMK cells cultured with
30 nmol L)1 factor V plus 125I-labeled factor V±plasma
concentrations of fibrinogen (10 lmol L)1), transferrin
(38 lmol L)1), factor VIII (0.3 nmol L)1), and IgG
(666 lmol L)1) for 1 h in serum-free medium (37 C). The
cells were washed extensively to ensure the removal of
membrane-bound radioactivity to quantify the amount of
125I-labeled factor V endocytosed.
To assess thrombin-induced secretion, CMKcells cultured in
serum-freemedia for 4 h with 30 nmol L)1 factor V containing
trace 125I-labeled factor V, were washed extensively to ensure
the removal of membrane-bound radioactivity, resuspended at
1 · 107 mL)1, and treated ±2 U mL)1 thrombin (5 min,
37 C) [38]. Bound and internalized 125I-labeled factor V was
separated from free 125I-labeled factor V by centrifugation
through oil, and the radioactivity associated with the cell
supernatants and pellets was determined.
Analyses of platelet endocytosis of fibrinogen and factor V
in whole blood
Blood was drawn by phlebotomy from consenting adults into
heparin (50 U mL)1). Aliquots of blood were incubated with
equal volumes of plasma concentrations of AlexaFluor488-
labeled fibrinogen (10 lmol L)1) or factor V (30 nmol L)1)
(60 min). Washed platelets were incubated (15 min) with anti-
CD41-PE (100 nmol L)1) or an equivalent concentration of
controlmouse IgG-PE. The platelets (10 000) were analyzed on
a Coulter EPICS Elite Flow Cytometer.
Results
Endocytosis of plasma factor V by CD34+ cell-derived
megakaryocytes
Human CD34+ bone marrow cells, subjected to ex vivo
expansion and differentiation into megakaryocytes under
serum-free conditions in the presence of stem cell factor
and thrombopoietin for 10 days, expressed no detectable,
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endogenous factor V subsequent to cell permeabilization and
immunocytochemical staining (Fig. 1A,C). In contrast, addi-
tion of a plasma concentration of factor V to the megakaryo-
cyte cultures on day 7 followed by identical analyses on day 10
demonstrated its intracellular localization (Fig. 1B) in those
cells immunostaining positively for CD41 (Fig. 1D).
Factor V endocytosis appeared to be developmentally
regulated (Fig. 2A). Addition of factor V to the cytokine-
stimulated megakaryocyte cultures on day 4 followed by flow
cytometric analyses on day 7 demonstrated that only a small
subpopulation of CD41+ megakaryocytes (5.9 ± 1.2%)
endocytosed factor V. In marked contrast, addition of factor
V on day 7 followed by flow cytometric analyses on day 10
resulted in substantial factor V uptake by 34 ± 3.8% of the
CD41+ megakaryocytes. Ploidy analyses of this same cell
population demonstrated that all of the CD41+ cells with
>4C DNA content (the more mature cell population) had
endocytosed factor V (Fig. 2B, bottom right) whereas a much
smaller percentage of the 2C/4C CD41+ cells was positive for
factor V uptake. In this series of experiments, culture of the
megakaryocytes in the presence of a plasma concentration of
factor IX did not result in any factor IX uptake, consistent with
its absence from platelets and megakaryocytes, and confirming
the specificity of factor V endocytosis.
In these experiments, and those described subsequently,
factor V endocytosis was not a result of its proteolysis over time
in culture. Western blots of supernatants, from cells incubated
with unmodified factor V using a mixture of mAbs against the
factor V light chain and heavy chain, or autoradiography of
supernatants from cells incubated with 125I-labeled factor V,
demonstrated that single-chain factor V remained intact
throughout the course of the experiments. However, subse-
quent to its endocytosis, substantial proteolysis occurred to
yield factor V fragments that appeared similar in size to those
stored in and released from platelets [39] (Bouchard et al.,
manuscript in preparation).
Endocytosis of plasma factor V by megakaryocyte-like cell
lines
Similar protocols were used to determine ifMEG-01 andCMK
cells endocytose factor V. Analyses of factor IX and fibrinogen
endocytosis served as negative and positive controls, respect-
ively. Cells cultured in the absence of exogenous factor V
showed no reactivity with the anti-factor V antibody following
cell permeabilization, confirming that neither cell line synthes-
izes factor V (data not shown). Identical analyses performed
subsequent to cell culture in the presence of plasma concen-
trations of factor V or fibrinogen demonstrated that subpop-
ulations of CMK andMEG-01 cells endocytose these proteins
(Table 1, top). A significantly greater proportion of both the
MEG-01 and CMK cell populations endocytosed fibrinogen
when compared to factor V; therefore, not every cell that
endocytoses fibrinogen, endocytoses factor V. Since treatment
A B
+ Exogenoas Factor V
+ Exogenoas Factor V
C D
Fig. 1. Immunocytochemical localization of factor V endocytosed by ex vivo-derived megakaryocytes. Ex vivo-derived megakaryocytes were cultured
in the presence (B, D) or absence (A, C) of plasma concentrations of factor V for 72 h. On day 10, adherent cell preparations were subjected to
immunocytochemical localization of factor V using anti-factor V (A, D) and/or anti-CD41 (C, D) monoclonal antibodies subsequent to cell
permeabilization. Controls using non-specific, isotyped-matched antibody or secondary antibody alone were uniformly negative (data not shown).
Immunostaining for factor V appears brown and immunostaining for CD41 appears pink. The cell nuclei are counterstained using Evans Blue.
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of MEG-01 and CMK cells with phorbol diesters induces
further differentiation along the megakaryocyte lineage
[36,40,41], a 2–3-fold increase in the number of CMK and
MEG-01 cells endocytosing factor V and fibrinogen was
observed as a result of PMA treatment (Table 1, top). Uptake
of factor IX could not be demonstrated under any of the
conditions examined.
In these experiments, the detection of cellular factor V and
fibrinogen with fluorescently labeled mAbs was absolutely
dependent upon cell permeabilization with Triton X-100,
indicating that the antigens were intracellular. To confirm these
observations directly, endocytosis was verified by confocal
microscopy of CMK cells, cultured in the presence of
AlexaFluor488-labeled factor V or fibrinogen, and extensively
washed to remove membrane-bound protein (Fig. 3). A
vertical (XZ) section through the region of the cells where the
majority of the fluorescent factor V or fibrinogen was observed
in the XY plane demonstrated that the visualized proteins were
located within the cell, and were absent from the cell membrane
surface (Fig. 3B).
Endocytosis of factor V and fibrinogen was independent of
the protein concentration to which the cells were exposed. Even
though the fibrinogen concentration used in these experiments
was 300 times greater than that of factor V (10 lmol L)1 vs.
30 nmol L)1), comparison of the relative amounts of endo-











































































































Fig. 2. Endocytosis of factor V by ex vivo-derived megakaryocytes is dependent upon the stage of megakaryocyte differentiation. (A) CD34+ bone
marrow-derived cells were cytokine stimulated for 7 or 10 days. Plasma concentrations of factor V or factor IX were added at days 4 or 7. Endocytosis was
analyzed using multiparameter flow cytometry subsequent to cell permeabilization using anti-CD41-PE, and AlexaFluor488-labeled anti-factor V or anti-
factor IX mAbs. The data represent the mean ±SEM (n ¼ 12). (B) CD34+ bone marrow-derived cells were cytokine stimulated for 10 days. At day 7,
factor V was added. At day 10, the cells were permeabilized, and stained with fluorophore-labeled antibodies and propidium iodide. Cells wer̀e analyzed by
multiparameter flow cytometry. Cells that were stained with propidium iodide and non-immune mAbs were used as controls.
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exceeded factor V endocytosis 3-fold (Table 1, bottom),
indicating that endocytosis of each of these proteins was
specific and differentially regulated. The amount of antigen
present in the cells was determined by calculation of a
fluorescence index – the product of the percentage of positive
cells and the mean fluorescence of that positive cell population.
This is a valid measure of the relative density of the proteins
associated with the cells as the AlexaFluor488-labeled mAbs
used had almost identical F : P ratios.
Consistent with this notion, the percentage of 125I-labeled
factor V endocytosed by cells (100%) was not significantly
affected by the presence of plasma concentrations of transferrin
(94.9%), IgG (95.4%), fibrinogen (87.4%), or factor VIII
(98.0%), whereas, a 50-fold molar excess of unmodified factor
V inhibited 125I-labeled factor V endocytosis by >98%. In
addition, another megakaryocyte-like cell line, CHRF-288,
endocytosed fibrinogen, but not factor V. In six different
experiments approximately the same proportion of CHRF-288
cells as CMK andMEG-01 cells endocytosed fibrinogen, while
virtually no endocytosed factor V could be detected. Although
PMA-treatment of CHRF-288 cells increased their expression
of CD41, factor V endocytosis was not induced. These
combined results are consistent with the hypothesis that factor
V and fibrinogen are endocytosed by megakaryocytes via
specific, membrane-binding events.
Endocytosis of 125I-labeled factor V by MEG-01 and CMK
cells was time-dependent. The amount of 125I-labeled factor V
associated withMEG-01 cells was maximal at 8 h (Fig. 4). The
subsequent gradual decrease in cell-associated factor V was not
the result of cell death, but rather appeared more consistent
with an increased rate of constitutive secretion vs. endocytosis
as MEG-01 cells do not possess a-granule-like structures [41].
In contrast, the amount of 125I-labeled factor V associated with
both unstimulated and PMA-stimulated CMK cells was
maximal at 6 h and could be sustained (Fig. 4, inset), perhaps
more consistent with the presence of a-granule-like structures
in these cells [38,40]. PMA stimulation resulted in a 3-fold
increase in factor V endocytosis, as observed previously
(Table 1).
Subsequent to a 4-h incubation with 125I-labeled factor V,
thrombin treatment of CMK cells [38] induced the release of
25% of the endocytosed 125I-labeled factor V consistent with
its partial localization to secretory granules. Furthermore, a
significant fraction of endocytosed, fluorescently labeled factor
V and fibrinogen colocalized within CMK cells (Fig. 5).
METAMORPH analysis of the boxed cell indicated that 73% of
the endocytosed factor V colocalized with endocytosed fibrin-
ogen, and 70% of the fibrinogen colocalized with factor V.
Since factor V and fibrinogen are stored in megakaryocyte
a-granules [42], one would anticipate that subsequent to their
specific and independent endocytosis, factor V and fibrinogen
would be sorted together to a-granule-like structures. It should
also be noted that some cells will only endocytose fibrinogen
(see Fig. 5), which is consistent with the flow cytometric
analyses demonstrating that a larger number of cells endo-
cytose fibrinogen when compared to factor V (see Table 1).
Factor V endocytosis appears specific to megakaryocytes.
Flow cytometric analyses of platelets in whole blood diluted
with plasma concentrations of fluorophore-labeled factor V
Table 1 Quantitative analyses of the endocytosis of factor V and
fibrinogen by megakaryocyte-like cells
Factor IX Factor V Fibrinogen
% positive cells*
CMK 2.9 ± 2.0 9.1 ± 3.4 13.2 ± 5.3
(+) PMA 0 16.2 ± 4.6 26.5 ± 7.6
MEG-01 0 7.7 ± 0.6 18.5 ± 1.1
(+) PMA 2.2 ± 2.2 20.2 ± 2.9 32.6 ± 7.9
Fluorescence Index
CMK 50 ± 50 300 ± 180 620 ± 280
(+) PMA 0 540 ± 260 920 ± 190
MEG-01 0 170 ± 40 470 ± 60
(+) PMA 50 ± 50 370 ± 160 850 ± 230
Megakaryocyte-like cells were cultured in serum-free medium in the
presence or absence of plasma concentrations of factor IX, factor V, or
fibrinogen for 16 h. Endocytosis was analyzed by immunostaining of
permeabilized cells using AlexaFluor488-labeled anti-factor IX, factor
V, or fibrinogen mAbs, labeled with the same F : P ratios, followed by
flow cytometry.
*The analyses regions were set such that  97% of the cells stained
with isotype-matched, non-immune antibodies were negative. The data
are presented as the mean percentage (± SD) of cells that immuno-
stained positively for each antibody (n ¼ 8).
The mean fluorescence index is defined as the product of the percent
positive cells and the mean cell fluorescence of that positive cell pop-









Fig. 3. Fluorescence micrograph of factor V or fibrinogen endocytosed by
megakaryocyte-like cell lines. (A) CMK cells were cultured in the presence
of AlexaFluor488-labeled factor V or fibrinogen for 4 h. Cells were visu-
alized using anOlympus BX50Upright FluorescenceMicroscope. In these
micrographs, the fluorescence images were overlayed on the phase contrast
images (original magnification ·600). (B) The laser was scanned repeat-
edly across the regions of the cells indicated by the yellow lines in (A) as the
focus motor was moved vertically through the images at different z-axis
positions to produce vertical sections of the images.
546 B. A. Bouchard et al
 2005 International Society on Thrombosis and Haemostasis
or fibrinogen demonstrated that >80% of the platelets
endocytosed fibrinogen. Less than 1% of the platelets were
positive for factor V, which is consistent with the observation
that factor V does not bind to the unactivated, human
platelet surface [14]. Thus, endocytosis of these two proteins
by megakaryocytes must be regulated by independent and
specific mechanisms.
Endocytosis of factor V by megakaryocytes occurs via a
clathrin-dependent, receptor-mediated event
The colocalization of factor V with transferrin was quantified,
because the cellular accumulation of transferrin is regulated by
clathrin-dependent, receptor-mediated endocytosis, and there-
fore is used as a tool to distinguish clathrin-dependent from
clathrin-independent endocytosis [43]. Subsequent to their
endocytosis by PMA-stimulated CMK cells, AlexaFluor488-
factor V accumulated in the same endocytic vesicles as
AlexaFluor568-transferrin in a time-dependent manner
(Fig. 6A). At 1 and 4 h, respectively, 66% and 75% of the
endocytosed factor V colocalized with endocytosed transferrin,
whereas  83% of the endocytosed transferrin was colocalized
with factor V. Incomplete colocalization was not surprising
because factor V, a storage protein, would probably only
follow transferrin to the early endosome.
Endocytosed, AlexaFluor488-factor V was also partially
colocalized with clathrin and a-adaptin, components of
clathrin-coated vesicles. AlexaFluor488-factor V was observed
within some of the same endocytic vesicles that stained
positively with anticlathrin and anti-a-adaptin antibodies
(Fig. 6B), following a 4-h incubation. METAMORPH analyses
of the merged images demonstrated that 84% of the endocy-
tosed factor V colocalized with clathrin, while 68% of the
clathrin was colocalized with factor V. Similarly, 61% of the
factor V colocalized with a-adaptin and 42% of the a-adaptin
colocalized with factor V. In separate experiments, similar
percentages of endocytosed transferrin colocalized with clath-
rin and a-adaptin ( 50%). These combined data support the
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Fig. 4. Time dependence of 125I-labeled factor V endocytosis by MEG-01 and CMK cells. MEG-01 cells were cultured in the presence of factor V
containing trace 125I-labeled factor V for 1–21 h. Cell-associated 125I-labeled factor V was determined at each time point by subtracting the radioactivity
at time ¼ 0 from the radioactivity associated with each aliquot. The data represent the mean ±SD of three determinations. Inset: Endocytosis of
125I-labeled factor V by untreated (s) or PMA-treated (d) CMK cells over time.
Factor V-AlexaFluor488 (green) Fibrinogen-AlexaFluor568 (red) Merged (Colocalization = yellow)
Fig. 5. Factor V colocalizes with fibrinogen subsequent to their endocytosis by megakaryocyte-like cells. PMA-stimulated CMK cells were cultured in
the presence of AlexaFluor488-labeled factor V (green fluorescence), or AlexaFluor568-labeled fibrinogen (red fluorescence) for 4 h. The individual images
were merged (yellow fluorescence) using Bio-Rad LASERPIX image analysis software. METAMORPH analyses were performed on the boxed cell, which
endocytosed both proteins.
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concept that factor V endocytosis by megakaryocytes appears
to be regulated by a clathrin-dependent process rather than a
pinocytotic mechanism.
Exposure of cells to hypertonicmedia for 15–30 min at 37 C
reduces membrane-attached clathrin lattices to non-functional
























Clathrin-AlexaFluor568 (red) Merged (Colocalization = yellow)
Factor V-AlexaFluor488 (green) α-adaptin-AlexaFluor568 (red) Merged (Colocalization = yellow)
Fig. 6. Factor V endocytosis by megakaryocyte-like cells is a clathrin-dependent process. (A) PMA-stimulated CMK cells were cultured in the presence
of AlexaFluor488-labeled factor V and AlexaFluor568-labeled transferrin for 1 or 4 h. The merged images are shown. (B) PMA-stimulated CMK cells
were also cultured in the presence of AlexaFluor488-labeled factor V (green fluorescence) for 4 h, and subsequently immunostained for clathrin or
a-adaptin, which was detected using a goat anti-mouse IgG-AlexaFluor568 (red fluorescence). The individual fluorescence images are shown in grey scale,
and the merged images are shown in color. Similar results were obtained using MEG-01 cells. (C) PMA-stimulated CMK cells were cultured in normal
tissue culture media (top) or hypertonic tissue culture media (bottom) and AlexaFluor488-labeled factor V, fibrinogen, or transferrin. The fluorescence
micrographs shown above were visualized and imaged using the same microscope settings.
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receptor-mediated endocytosis [44].CultureofPMA-stimulated
CMK cells, in media made hypertonic by the addition of
0.45 mol L)1 sucrose,whilenotaffectingcell viabilitydrastically
reduced their ability to endocytose factor V, transferrin
and fibrinogen (also known to be endocytosed via a clathrin-
dependent, receptor-mediated mechanism [45]) (Fig. 6C,
bottom vs. top). Flow cytometric analyses of and calculation
of fluorescence indices for these cell populations demonstrated
that the amounts of factor V, fibrinogen and transferrin
endocytosed by cells cultured in hypertonic media were
decreased by 86, 94 and 70%, respectively, as compared
to cells cultured in normal media. Taken together, these
observations clearly demonstrate that factor V is endocytosed
by megakaryocytes via a clathrin-dependent process.
Discussion
These studies are the first to directly demonstrate that
megakaryocytes endocytose factor V. Thus, the acquisition of
plasma-derived factor V by patients subsequent to liver
transplant was not a function of the antirejection medication
the patients were receiving, engraftment of stem cells derived
from the transplanted liver, or an inability of the patients’
megakaryocytes to synthesize protein. This endocytic process is
developmentally regulated during megakaryocyte differenti-
ation, is specific, and regulated at the membrane surface by a
clathrin-dependent, and most likely receptor-mediated event,
such that endocytosed factor V is subsequently trafficked to
secretory granule-like structures. In these studies, endocytosed
factor V partially colocalized with components of clathrin-
coated vesicles and endocytosis could be inhibited by cell
culture in hypertonic media, observations consistent with
several studies performed in different cell systems demonstra-
ting the clathrin-dependence of other endocytosed proteins
[46–50]. Furthermore, plasma concentrations of transferrin and
fibrinogen, two proteins known to be endocytosed by megak-
aryocytes, had no effect on the endocytosis of factor V. These
data also indicate that endogenous synthesis of factor V
accounts for an insignificant fraction of the total megakaryo-
cyte intracellular pool, which is consistent with other studies
that demonstrate that factor V mRNA is undetectable in
megakaryocytes derived from peripheral blood [51]. Similarly,
factor V antigen was undetectable in megakaryocytes derived
from bone marrow cultured in its absence, indicating that less
than 0.05% of the total platelet-derived factor V was endog-
enously synthesized by these cells [52]. In contrast to these
observations, Gewirtz and colleagues, using metabolic labeling
studies, demonstrated that mature human megakaryocytes
synthesize factor V [53], and they subsequently identified factor
V mRNA in pure megakaryocyte populations [54]. Interest-
ingly, in the latter study, the factor V steady-state mRNA levels
did not change as a result of cell culture with phorbol diester in
the presence of serum, whereas factor V antigen levels increased
under these same conditions. This latter observation is
consistent with the results of the present study that clearly
demonstrates endocytosis of factor V by megakaryocytes
following their differentiation by cytokines and phorbol diester.
These combined observations are analogous to the results of
several studies demonstrating that the platelet fibrinogen pool
is derived exclusively from megakaryocyte or platelet endo-
cytosis of fibrinogen from the plasma [6–8], despite the presence
of mRNA in these cells [9].
Several studies from our laboratory indicate that platelet-
derived factor V is both physically and functionally distinct
from its plasma counterpart [13,16,17]. Platelet-derived factor
V is resistant to phosphorylation catalyzed by a platelet-
associated casein kinase II-like enzyme. In contrast to
plasma-derived factor V, which circulates as a single-chain
molecule, platelet-derived factor V is stored in a-granules in a
partially proteolytically activated state. Characterization of
purified platelet-derived factor V indicated that while the heavy
chain is intact, the platelet-derived factor V light chain has a
unique cleavage at Tyr1543, which leads to functional cofactor
activity. Furthermore, the platelet-derived factor V heavy chain
possesses a unique O-linked glycoform on Thr402. Based on
these and other observations, we hypothesize that prior to its
targeting to a-granules, endocytosed plasma factor V is
retailored post-translationally to yield the functional cofactor
molecule.
Our laboratory’s observations are the first to demonstrate
modifications of a protein subsequent to its endocytosis that
alter its function. Thus, the intracellular trafficking pathways
that direct endocytosed factor V to the a-granule are of
interest. In cultured human megakaryocytes and the megak-
aryocyte-like cell line, CHRF-288, Sixma and colleagues
distinguished three types of granules by electron microscopy:
multivesicular bodies type I (MVB I), MVB II, and a-granules
[55]. Using gold-labeled albumin and fibrinogen, they dem-
onstrated that MVBs appear to be endocytic compartments,
which may function as precursors to a-granules. Furthermore,
because endogenously synthesized megakaryocyte proteins
such as VWF were also found in MVBs, proteins may be
trafficked directly from the Golgi to MVBs [55]. An alternat-
ive hypothesis based on the collective data is that subsequent
to their endocytosis by megakaryocytes, proteins are trafficked
from the endosome to the Golgi to MVBs, which would allow
for modification of the endocytosed protein. Based on the
data obtained to date, we believe that CD34+ cell-derived
megakaryocytes, as well as MEG-01 and CMK cells, will be
useful as model systems to begin to test these hypotheses.
Since the concentration of platelet-derived factor V can be
<100 times that of its plasma counterpart at a site of injury
[24], its unique functional properties will have a distinct
advantage over plasma-derived factor V. Thus, studies of the
origin and unique characteristics of platelet-derived factor V
are essential for a relevant understanding of procoagulant
events. Furthermore, identification of the megakaryocyte
membrane receptor that mediates factor V binding and its
subsequent endocytosis is also of great interest as endocytosis
of factor V by megakaryocytes, but not platelets, represents a
novel mechanism whereby platelets acquire an essential
hemostatic protein.
Endocytosis of plasma factor V by megakaryocytes 549
 2005 International Society on Thrombosis and Haemostasis
Acknowledgements
These studies would not have been possible without the
generous donations of CMK and CHRF-288 cells by
Drs Hava Avraham (Harvard Medical School) and Michael
Lieberman (University of Cincinnati College of Medicine),
respectively. The authors would also like to thankLorna Seifert
and Jennifer Bombard for their technical assistance. This work
was supported by HL70826 (to PBT), HL46703 (Project 4) (to
PBT) and the Department of Biochemistry, University of
Vermont College of Medicine.
References
1 Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von
Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76:
1102–6.
2 Sitar G, Borroni R, Pesce G. Synthesis of thrombospondin and
glycoprotein IIb-IIIa by a purified megakaryocyte human bone
marrow culture. Haematologica 1986; 71: 389–93.
3 Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen
activator inhibitor-1 mRNA is expressed in platelets and megak-
aryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler
Thromb 1993; 13: 669–74.
4 Hill SSSG, Joshua P, Ribau J, Austin RC, Podor TJ. Differential
mechanisms targeting type I plasminogen activator inhibitor and
vitronectin into the storage granules of a human megakaryocytic cell
line. Blood 1996; 87: 5061–73.
5 Roussi JDL, Sigman J, Vaiman M, Pignaud G, Bonneau M,
Martin Cramer E. Absence of incorporation of plasma von Wille-
brand factor into porcine platelet a-granules. Br J Haematol 1995; 90:
661–8.
6 Cramer EM, Debili N, Martin JF, Gladwin AM, Breton-Gorius J,
Harrison P, Savidge GF, Vainchenker W. Uncoordinated expres-
sion of fibrinogen compared with thrombospondin and von Wille-
brand factor in maturing human megakaryocytes. Blood 1989; 73:
1123–9.
7 Handagama P, Scarborough RM, Shuman MA, Bainton DF.
Endocytosis of fibrinogen into megakaryocyte and platelet alpha-
granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa)
[published erratum appears in Blood 1993; 82 (9): 2936]. Blood 1993;
82: 135–8.
8 Louache F, Debili N, Cramer E, Breton-Gorius J, Vainchenker W.
Fibrinogen is not synthesized by human megakaryocytes. Blood 1991;
77: 311–16.
9 Podolak-Dawidziak M, Hancock V, Lelchuk R, Kotlarek-Haus S,
Martin JF. The expression of mRNA for fibrinogen in megakaryo-
cytes isolated from patients with T-cell lymphoma. Br J Haematol
1995; 91: 362–6.
10 Poujol C, Nurden AT, Nurden P. Ultrastructural analysis of the
distribution of the vitronectin receptor (alpha v beta 3) in human
platelets and megakaryocytes reveals an intracellular pool and
labelling of the alpha-granule membrane. Br J Haematol 1997; 96:
823–35.
11 Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human
platelet-derived factor V originates from the plasma pool. Blood 1998;
92: 3035–41.
12 Christella M, Thomassen LG, Castoldi E, Tans G, Magdeleyns EJ,
Delaunoit C, Debusscher L, Van Assche KJ, Rosing J. Endogenous
factor V synthesis in megakaryocytes contributes negligibly to the
platelet factor V pool. Haematologica 2003; 88: 1150–6.
13 Gould WR, Simioni P, Silveira JR, Tormene D, Kalafatis M, Tracy
PB. Megakaryocytes endocytose and subsequently modify human
factor V in vivo to form the entire pool of a unique platelet-derived
cofactor. J Thromb Haemost 2005; 3: 450–6.
14 Tracy PB, Eide LL, Mann KG. Human prothrombinase complex
assembly and function on isolated peripheral blood cell populations.
J Biol Chem 1985; 260: 2119–24.
15 Mazzorana M, Baffet G, Kneip B, Launois B, Guguen-Guillouzo C.
Expression of coagulation factor V gene by normal adult human
hepatocytes in primary culture. Br J Haematol 1991; 78: 229–35.
16 Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of
coagulation factor V produce a physically and functionally distinct
platelet-derived cofactor: characterization of purified platelet-derived
factor V/Va. J Biol Chem 2004; 279: 2383–93.
17 Monkovic DD, Tracy PB. Functional characterization of human
platelet-released factor V and its activation by factor Xa and throm-
bin. J Biol Chem 1990; 265: 17132–40.
18 Monkovic DD, Tracy PB. Activation of human factor V by factor Xa
and thrombin. Biochemistry 1990; 29: 1118–28.
19 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation
of human factor V and human factor Va by activated protein C. J Biol
Chem 1994; 269: 31869–80.
20 Camire RM, Kalafatis M, CushmanM, Tracy RP, Mann KG, Tracy
PB. The mechanism of inactivation of human platelet factor Va from
normal and activated protein C-resistant individuals. J Biol Chem
1995; 270: 20794–800.
21 Conlon SJ, Camire RM, Kalafatis M, Tracy PB. Cleavage of platelet-
derived factor Va by plasmin results in increased and sustained co-
factor activity on the thrombin-activated platelet surface. Thromb
Haemost 1997; 77: 2507a.
22 Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-
derived factor Va/Va Leiden cofactor activities are sustained on the
surface of activated platelets despite the presence of activated protein
C. Blood 1998; 91: 2818–29.
23 Tracy PB, Mann KG. Abnormal formation of the prothrombinase
complex: factor V deficiency and related disorders.Hum Pathol 1987;
18: 162–9.
24 NesheimME,NicholsWL, Cole TL, Houston JG, SchenkRB,Mann
KG, Bowie EJ. Isolation and study of an acquired inhibitor of human
coagulation factor V. J Clin Invest 1986; 77: 405–15.
25 Yang TL, Pipe SW, Yang A, Ginsburg D. Biosynthetic origin and
functional significance of murine platelet factor V. Blood 2003; 102:
2851–5.
26 SunH, Yang TL, Yang A,Wang X, Ginsburg D. The murine platelet
and plasma factor V pools are biosynthetically distinct and sufficient
for minimal hemostasis. Blood 2003; 102: 2856–61.
27 Chiu HC, Schick PK, Colman RW. Biosynthesis of factor V
in isolated guinea pig megakaryocytes. J Clin Invest 1985; 75: 339–46.
28 Tracy PB, Peterson JM, Nesheim ME, McDuffie FC, Mann KG.
Interaction of coagulation factor V and factor Va with platelets. J Biol
Chem 1979; 254: 10354–61.
29 Cerveny TJ, Fass DN, Mann KG. Synthesis of coagulation factor V
by cultured aortic endothelium. Blood 1984; 63: 1467–74.
30 JennyRJ, PittmanDD, Toole JJ, Kriz RW,AldapeRA,HewickRM,
Kaufman RJ, Mann KG. Complete cDNA and derived amino acid
sequence of human factor V.Proc Natl Acad Sci USA 1987; 84: 4846–
50.
31 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons
C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second
thrombin receptor in humans. Nature 1997; 386: 502–6.
32 Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of
functional human coagulation factor V by using a hybridoma anti-
body. Proc Natl Acad Sci USA 1981; 78: 162–6.
33 Straughn W 3rd, Wagner RH. A simple method for preparing
fibrinogen. Thromb Diath Haemorrh 1966; 16: 198–206.
34 Williams JL, Pipia GG, Datta NS, Long MW. Thrombopoietin
requires additional megakaryocyte-active cytokines for optimal
ex vivo expansion of megakaryocyte precursor cells. Blood 1998; 91:
4118–26.
35 Taniguchi Y, London R, Schinkmann K, Jiang S, Avraham H. The
receptor protein tyrosine phosphatase, PTP-RO, is upregulated
550 B. A. Bouchard et al
 2005 International Society on Thrombosis and Haemostasis
during megakaryocyte differentiation and is associated with the c-Kit
receptor. Blood 1999; 94: 539–49.
36 Fugman DA, Witte DP, Jones CL, Aronow BJ, Lieberman MA.
In vitro establishment and characterization of a human megakar-
yoblastic cell line. Blood 1990; 75: 1252.
37 Chuang JL, Schleef RR. Adenovirus-mediated expression and pack-
aging of tissue-type plasminogen activator in megakaryocytic cells.
Thromb Haemost 2001; 85: 1079–85.
38 Nagano T, Kishimoto Y, Kimura T, YasunagaK, AdachiM, Ryo R,
Sato Tet al. Ultrastructural analysis of a human megakaryocytic le-
ukemia cell line (CMK11-5) in response to platelet agonists. Int J
Hematol 1993; 57: 73–80.
39 Bouchard BA, Thanassi NM, Tracy PB. Factor V endocytosed
and retained by megakaryocytes is proteolytically processed by an
intracellular protease to form the platelet-derived factor V pool.
J Thrombosis Hemostasis 2003; 1: P1335.
40 Nagano T, Taniguchi H, Hamamoto K. Ultrastructural analysis of
incorporation into organelles of CMK cells. J Clin Electron Micros-
copy 1989; 22: 5–6.
41 Ogura M, Morishima Y, Okumura M, Hotta T, Takamoto S, Ohno
R,Hirabayashi N,NaguraH, SaitoN. Functional andmorphological
differentiation induction of a human megakaryoblastic leukemia cell
line (MEG-01s) by phorbol diesters. Blood 1988; 72: 49–60.
42 Harrison P, Cramer EM. Platelet a-granules. Blood Rev, 1993:
52–62.
43 Bayer N, Schober D, Huttinger M, Blaas D, Fuchs R. Inhibition of
clathrin-dependent endocytosis has multiple effects on HRV2 cell
entry. J Biol Chem 2000; 276: 3952–62.
44 Heuser JE, Anderson RG. Hypertonic media inhibit receptor-
mediated endocytosis by blocking clathrin-coated pit formation.
J Cell Biol 1989; 108: 389–400.
45 Klinger MH, Kluter H. Immunocytochemical colocalization of
adhesive proteins with clathrin in human blood platelets. Further
evidence for coated vesicle-mediated transport of von Willebrand
factor, fibrinogen and fibronectin. Cell Tissue Res 1995; 279: 453–7.
46 Barlic J, Khandaker MH, Mahon E, Andrews J, DeVries ME,
Mitchell GB, Rahimpour R, Tan CM, Ferguson SS, Kelvin DJ.
b-arrestins regulate interleukin-8-induced CXCR1 internalization.
J Biol Chem 1999; 274: 16287–94.
47 Cao H, Orth JD, Chen J, Weller SG, Heuser JE, McNiven MA.
Cortactin is a component of clathrin-coated pits and participates in
receptor-mediated endocytosis. Mol Cell Biol 2003; 23: 2162–70.
48 Teo M, Tan L, Lim L, Manser E. The tyrosine kinase ACK1 asso-
ciates with clathrin-coated vesicles through a binding motif shared by
arrestin and other adaptors. J Biol Chem 2001; 276: 18392–8.
49 Wei ML, Bonzelius F, Scully RM, Kelly RB, Herman GA. GLUT4
and transferrin receptor are differentially sorted along the endocytic
pathway in CHO cells. J Cell Biol 1998; 140: 565–75.
50 Memmo LM, McKeown-Longo P. The alphavbeta5 integrin func-
tions as an endocytic receptor for vitronectin. J Cell Sci 1998; 111:
425–33.
51 GiampaoloA, Vulcano F,MacioceG,Mattia G, BarcaA,Milazzo L,
Orlando M, Hassan HJ. Factor V expression in human in vitro
developed megakaryocytes. Thromb Haemost 2001; 86: 542a.
52 Veljkovic D, Cramer EM, Alimardani G, Fichelson S, Masse JM,
Hayward CPM. Studies of alpha-granule proteins in cultured human
megakaryocytes. Thromb Haemost 2003; 90: 844–52.
53 Gewirtz AM, KeeferM, Doshi K, Annamalai AE, Chiu HC, Colman
RW. Biology of human megakaryocyte factor V. Blood 1986; 67:
1639–48.
54 Gewirtz AM, Shapiro C, Shen YM, Boyd R, Colman RW. Cellular
and molecular regulation of factor V expression in human mega-
karyocytes. J Cell Phys 1992; 153: 277–87.
55 Heijnen HFG, Debili N, Vainchencker W, Breton-Gorius J, Geuze
HJ, Sixma JJ. Multivesicular bodies are an intermediate stage in the
formation of platelet a-granules. Blood 1998; 91: 2313–25.
Endocytosis of plasma factor V by megakaryocytes 551
 2005 International Society on Thrombosis and Haemostasis
